Evidence map›Paper›PMID 41346243›Full record

ArticleNanomedicine (London, England)2025

Inhibition of calreticulin by protein nanoparticles carrying antisense oligonucleotides reduce gene expression and infection of

B Prestegui-Martel, I Martínez, R E Cárdenas-Guerra, A K Cortés-Coss, X Del Toro-Ríos, A Hernández-Garcia, B Espinoza

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nanomedicine (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

B Prestegui-MartelLaboratorio de estudios sobre tripanosomiasis y Leishmaniasis, Departamento de Inmunología, Instituto de Investigaciones Biomédicas, Universidad Nacional Autónoma de México, Ciudad de México, México.
I MartínezLaboratorio de estudios sobre tripanosomiasis y Leishmaniasis, Departamento de Inmunología, Instituto de Investigaciones Biomédicas, Universidad Nacional Autónoma de México, Ciudad de México, México.
R E Cárdenas-GuerraLaboratorio de Ingeniería Biomolecular y Bionanotecnología, Departamento de Química de Biomacromoléculas, Instituto de Química, Universidad Nacional Autónoma de México, Ciudad de México, México.
A K Cortés-CossLaboratorio de Ingeniería Biomolecular y Bionanotecnología, Departamento de Química de Biomacromoléculas, Instituto de Química, Universidad Nacional Autónoma de México, Ciudad de México, México.
X Del Toro-RíosLaboratorio de Ingeniería Biomolecular y Bionanotecnología, Departamento de Química de Biomacromoléculas, Instituto de Química, Universidad Nacional Autónoma de México, Ciudad de México, México.
A Hernández-GarciaLaboratorio de Ingeniería Biomolecular y Bionanotecnología, Departamento de Química de Biomacromoléculas, Instituto de Química, Universidad Nacional Autónoma de México, Ciudad de México, México.
B EspinozaLaboratorio de estudios sobre tripanosomiasis y Leishmaniasis, Departamento de Inmunología, Instituto de Investigaciones Biomédicas, Universidad Nacional Autónoma de México, Ciudad de México, México.

Funding

SECIHTIUNAM-PAPIIT
6 · The paper itself

Abstract

backgroundChagas disease, caused by the parasite

methodsThe strategy was based on the use of a virus-inspired protein (CB

resultsThe results showed that CRT, Super Oxide Dismutase, and Glutathione Peroxidase presented gene expression reduction. Decreased parasite survival, altered parasite morphology, increased complement susceptibility, produced metabolic alteration, and substantially reduced mammal cell infection were also observed.

conclusionThe results indicate that protein nanoparticles carrying antisense oligonucleotides are a promising strategy directed against

Indexed as

CalreticulinChagas DiseaseNanoparticlesOligonucleotides, AntisenseTrypanosoma cruziAnimalsHumansProtozoan ProteinsCalreticulinOligonucleotides, AntisenseProtozoan Proteinsantisense oligonucleotidescalreticulinChagas diseasegene expression reductionprotein nanoparticles

Identifiers

PMID41346243
PMCPMC12710951

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.